NEXT SCIENCE®

ASX ANNOUNCEMENT / MEDIA RELEASE

16 April 2024

Publication of study showing significant efficacy of XPERIENCE™ in reducing infection when used in Total Knee Arthroplasty

Next Science Limited (ASX:NXS) ("Next Science" or "the Company") today announces the publication of a study which demonstrates the efficacy of XPERIENCE™ in decreasing periprosthetic joint infection (PJI) following a Total Knee Arthroplasty (TKA).

Next Science is a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health.

The study entitled "Real World Evidence of the Impact of a Novel Surgical Irrigant on Surgical Site Infections in Primary Total Knee Arthroplasty Performed at an Ambulatory Surgery Center" by Dr Ronald W. Singer MD has been published in the *Journal of Surgical Infections.*

It can be accessed via the following link: [Surgical Infections | Vol 25, Issue 3 / April 2024](#)

The primary objective of the retrospective study was to evaluate the impact of Next Science's advanced surgical irrigation product, XPERIENCE™ on surgical site infections (SSI) in primary TKA performed at an ambulatory surgery centre.

Among the 524 primary TKA surgeries, one instance of PJI was diagnosed within 90 days of index surgery which was attributed to an exogenously acquired upper respiratory tract infection. The 0.19% PJI incidence rate indicated significant efficacy of XPERIENCE™ in decreasing PJI.

Dr Singer concluded that XPERIENCE™ is a "promising intraoperative antimicrobial irrigant that can be easily incorporated into a broader infection prevention strategy".

Next Science's CEO and Managing Director I.V. Hall said: "The study by leading orthopaedic surgeon Dr Ronald Singer shows that the use of XPERIENCE™ can improve patient outcomes by reducing infection when used in Total Knee Arthroplasty procedures. The results have been through a peer review process and their publication in the *Journal of Surgical Infections* adds to our growing body of clinical evidence for XPERIENCE™ and leads to broader recognition in the Orthopaedic community. We will continue to work closely with surgeons to conduct clinical research that further investigates the effectiveness of Next Science's products."

Approved and authorised for release by the Managing Director.

HEALING PEOPLE SAVING LIVES

Media & Investor Enquiries

Françoise Dixon
Phone: +61 412 292 977
Email: fdixon@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as "believes", "considers", "could", "estimates", "expects", "intends", "may" and other similar worlds that involve risks and uncertainties. Such statements are not guarantees of future performance and involved known and unknown risks uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

Next Science Limited ACN 622 382 549
Level 14, Australia Square,
264-278 George Street, Sydney NSW 2000
www.nextscience.com

HEALING PEOPLE SAVING LIVES

Page | 2